Bellerophon Therapeutics, Inc. ( BLPH) Stock. Should you Buy or Sell? $ 1.21
-0.01 (-0.83 %)
Bellerophon Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | BLPH |
| Price | $1.21 |
| Beta | -0.118 |
| Volume Avg. | $38.89 thousand |
| Market Cap | $11.55 M |
| 52 Week Range | $0.67 - $4.49 |
Bellerophon Therapeutics, Inc. opened the day at $1.21 which is -0.83 % on yesterday's close. Bellerophon Therapeutics, Inc. has a 52 week high of $4.49 and 52 week low of $0.67, which is a difference of $3.82. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $11.55 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Bellerophon Therapeutics, Inc. for $11.55 M, it would take 15 years to get your money back. Bellerophon Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Bellerophon Therapeutics, Inc. Stock Forecast - Is Bellerophon Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.803 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Bellerophon Therapeutics, Inc.
| Price Book Value Ratio | 0.941 | Price To Book Ratio | 0.941 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.803 |
How liquid is Bellerophon Therapeutics, Inc.
| Current Ratio | 3.118 |
| Quick Ratio | 2.997 |
Debt
| Debt Ratio | 0.307 | Debt Equity Ratio | 0.444 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Bellerophon Therapeutics, Inc.
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.
The stock price of Bellerophon Therapeutics Inc (NASDAQ: BLPH) increased by 34.6% in the previous trading session. This is why it happened.
Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.
About Bellerophon Therapeutics, Inc.
Description :
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
